Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population
Journal of Personalized Medicine · 31.01.2024 · 14 (2) · 166
DOI: 10.3390/jpm14020166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 31.01.2024. Verfasst von Lindsey Wells und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lindsey Wells ND LLC, Wilton, CT 06897, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Religen, Inc. (Plymouth Meeting, PA, USA).
Abstract (Originalsprache)
The folate receptor alpha autoantibodies (FRAAs) are associated with cerebral folate deficiency (CFD) and autism spectrum disorder (ASD). Both of these syndromes have overlapping characteristics with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). Thus, we propose that the FRAAs may contribute to the symptomatology of PANS/PANDAS. To test this hypothesis, 1 mL of serum from 47 patients (age range = 6–18 years old) clinically diagnosed with PANS/PANDAS was sent to Vascular Strategies (Plymouth Meeting, PA, USA) for analysis of FRAAs. Moreover, 63.8% of PANS/PANDAS patients (male = 15; female = 15) were found to have either the blocking and/or blinding FRAAs, with 25 (83.3%; male = 14; female = 11) having binding FRAAs, two (6.7%; all female = 2) having blocking FRAAs, and 3 (10%; male = 1; female = 2) having both binding and blocking. Furthermore, surprisingly, ASD was associated with a 0.76 lower binding titer (p = 0.02), and severe tics were associated with a 0.90 higher binding titer (p = 0.01). A case of a FRAA-positive patient is provided to illustrate that a treatment plan including leucovorin can result in symptom improvement in patients with PANS/PANDAS who are FRAA-positive. These data, for the first time, demonstrate that PANS/PANDAS is associated with FRAAs and suggest folate metabolism abnormalities may contribute to PANS/PANDAS symptomatology. Further studies investigating the therapeutic nature of leucovorin in the treatment of PANS/PANDAS are needed. Such studies may open up an alternative, safe, and well-tolerated treatment for those with the PANS/PANDAS diagnosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lindsey Wells ND LLC, Wilton, CT 06897, USA.
- Nancy O'Hara and Associates LLC, Wilton, CT 06897, USA.
- Autism Discovery and Treatment Foundation, Phoenix, AZ 85050, USA.
- Massachusetts General Hospital, Boston, MA 02114, USA.
- Natural Pediatrics of CT, Stamford, CT 06905, USA.
ORCID-Profile: Richard E Frye
Förderung
- Religen, Inc. (Plymouth Meeting, PA, USA)
Zitieren
APA
Wells, L., O'Hara, N., Frye, R. E., Hullavard, N., & Smith, E. (2024). Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population. Journal of Personalized Medicine, 14(2), 166. https://doi.org/10.3390/jpm14020166
Vancouver
Wells L, O'Hara N, Frye RE, Hullavard N, Smith E. Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population. Journal of Personalized Medicine. 2024;14(2):166. doi:10.3390/jpm14020166
BibTeX
@article{Wells2024,
author = {Wells, Lindsey and O'Hara, Nancy and Frye, Richard E and Hullavard, Neeshi and Smith, Erica},
title = {Folate Receptor Alpha Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) Population},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {2},
pages = {166},
doi = {10.3390/jpm14020166}
}
EUVIMED